Polly Murphy

Direttore/Membro del Consiglio presso CELCUITY INC.

Patrimonio netto: 164 493 $ in data 31/05/2024

59 anni

Health Technology

Consumer Services

Profilo

Polly A.
Murphy is an Independent Director at Atea Pharmaceuticals, Inc., Celcuity, Inc., and Chief Business Officer at UroGen Pharma Ltd.
She previously worked as Vice President-Commercial Development at Pfizer Inc. from 2019 to 2020 and as Senior VP-Business & Scientific Services at The Scripps Research Institute from 2005 to 2008.
Murphy holds a doctorate from Iowa State University and an MBA from Nova Southeastern University, Inc.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
ATEA PHARMACEUTICALS, INC. 0.03%	24/04/2024	23 295 ( 0.03% )	85 493 $	31/05/2024
CELCUITY INC. 0.02%	04/06/2024	5 000 ( 0.02% )	79 000 $	31/05/2024

Posizioni attive di Polly Murphy

Società	Posizione	Inizio
UROGEN PHARMA LTD.	Corporate Officer/Principal	09/09/2020
ATEA PHARMACEUTICALS, INC.	Direttore/Membro del Consiglio	01/08/2020
CELCUITY INC.	Direttore/Membro del Consiglio	12/09/2022

Tutte le posizioni attive di Polly Murphy

Precedenti posizioni note di Polly Murphy

Società	Posizione	Fine
PFIZER, INC.	Corporate Officer/Principal	01/08/2020
The Scripps Research Institute The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.	Corporate Officer/Principal	01/08/2008